Cost-Effectiveness of Incretin Therapies: A Canadian Lens on Diabetes, Obesity, and Emerging Indications — VialBase Research
medium
- GLP-1 receptor agonists and dual agonists (semaglutide, tirzepatide) are now among Canada's costliest outpatient drug classes
- Review synthesizes clinical and economic evidence on cost-effectiveness of incretins for T2DM and weight loss
- Canadian health-technology-assessment (HTA) frameworks have recognized limitations when evaluating incretins — the authors highlight price, patient selection, and long-term outcome uncertainty as key issues
- Emerging indications (MASH, cardiovascular outcomes, addiction, sleep apnea, obesity-related pain) complicate the cost-effectiveness calculus because traditional HTA models were built around narrower T2DM use
- Implications extend beyond Canada — any payer system weighing public coverage of incretins faces similar modeling gaps
Cost-Effectiveness of Incretin Therapies: A Canadian Lens on Diabetes, Obesity, and Emerging Indications
Summary
Narrative review from authors at the University of Toronto, Women’s College Hospital, and Western University synthesizing clinical and health-economics evidence on Semaglutide, Tirzepatide, and other incretin therapies. The review is framed around Canadian reimbursement but the analytical framework applies to any payer system that uses HTA to decide public coverage.
Not a primary study — this is a synthesis paper useful for understanding where the cost/benefit discussion is headed as emerging indications (cardiovascular, MASH, sleep apnea, addiction) broaden the population eligible for long-term incretin therapy.
Key Findings
- Incretins are now a major cost driver in Canadian outpatient pharmacy spending, on par with or exceeding legacy blockbuster classes
- Traditional HTA frameworks were designed for narrower T2DM use and struggle with the breadth of emerging incretin indications
- Key unresolved modeling questions: long-term weight-loss durability (especially post-discontinuation), comparative effectiveness between GLP-1 monotherapy and dual agonists, and how to value prevention of downstream cardiovascular/renal events
- Price, patient selection criteria, and outcome measure choice all materially move cost-effectiveness ratios
Methodology
- Narrative synthesis of clinical trial evidence + Canadian and international economic models
- No new primary data
- Canadian HTA context (CADTH / INESSS) but explicitly international in scope
Limitations
- Narrative review, not systematic — selection bias possible
- Models it references depend on assumptions that are themselves contested (discount rate, time horizon, willingness-to-pay threshold)
- Published April 2026, so newer Wegovy 7.2 mg approval (FDA-Wegovy-7mg-Priority-Voucher-Approval-Mar-2026) not reflected
Relevance to Content
Most VialBase readers care less about payer cost-effectiveness than individual efficacy, but this paper is useful for two editorial angles:
- Framing the “why is compounded GLP-1 a big deal” story — when branded GLP-1s are this expensive per-QALY in a single-payer system, the economics of compounded alternatives become more legible even as regulatory enforcement tightens (see FDA-Telehealth-GLP1-Warning-Letters-Mar-2026).
- Emerging indications primer — the review’s taxonomy of new indications (MASH, CV outcomes, addiction, sleep apnea) is a useful signal of where next-generation research is concentrating, which feeds into content planning on compound profile pages.
Useful for:
- A policy/market-context guide on “why are GLP-1s so expensive”
- A “where is GLP-1 research heading” landscape piece